Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06526988 · ClinicalTrials.gov registry record · NA

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

A NA study of Heart Failure With Reduced Ejection Fraction, sponsored by University of Colorado, Denver.

Recruiting
Registry status
NA
Development phase
2,200
Enrollment target
5
Study locations

NCT06526988 is a NA study of Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 2,200 participants, below the 3,884-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (43% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06526988, a NA study of Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by University of Colorado, Denver.

RECRUITING
Registry status
NA
Development phase
2,200 participants
Enrollment target
5
Study locations

Study Summary

An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of life, and survival.1,2 However, GDMT underuse occurs for the vast majority of patients with HFrEF. Two recent trials demonstrated improved GDMT prescribing during a clinic visit, each using automated delivery of a patient-centered decision support tool to promote a proactive and holistic approach to prescribing: EPIC-HF (NCT03334188) tested a brief video and checklist document sent to patients just prior to a clinic visit encouraging them to work with their clinicians to make at least 1 positive change to their GDMT; PROMPT-HF (NCT05433220) tested tailored electronic health record (EHR) alerts for GDMT intensification delivered to clinicians during clinic visits. The current I-I-CAPTAIN-HF study aims to broadly implement and test the EPIC-HF patient-facing and PROMPT-HF clinician-facing tools for HFrEF medication intensification at 5 health systems around the country through a pragmatic cluster-randomized implementation-effectiveness trial. This will occur through an initial phase of adaptation of the 2 tools at each health system. Once ready, the 2 tools will be tested using a 2x2 randomization at the clinician-level. In parallel, formal assessment of the implementation of EPIC-HF and PROMPT-HF will work to understand the most effective means of intervention design and delivery, as well as adaptations due to contextual factors to optimize use.

Interventions

  • BEHAVIORAL EPIC-HF Patient-facing Tool
  • BEHAVIORAL PROMPT-HF Clinician-facing Alert

Study Locations (5)

California

  • Sutter Health - Walnut Creek

Colorado

  • University of Colorado - Aurora

Connecticut

  • Yale University - New Haven

Illinois

  • Northwestern University - Chicago

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 2,200 participants
Start Date 2025-03-06
Est. Completion 2028-09-01
Phase NA

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT06526988

The ClinicalTrials.gov registry entry for NCT06526988 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,884-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (43% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which EPIC-HF Patient-facing Tool is the first listed.

NCT06526988 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06526988 about?

NCT06526988 is a clinical study titled "Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure". An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of li...

What is the current status of trial NCT06526988?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,200 participants. The study started on 2025-03-06. Estimated completion is 2028-09-01.

What conditions does trial NCT06526988 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction.

What interventions are being tested in trial NCT06526988?

The interventions under investigation include: EPIC-HF Patient-facing Tool (BEHAVIORAL), PROMPT-HF Clinician-facing Alert (BEHAVIORAL).

Who is sponsoring clinical trial NCT06526988?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06526988 being conducted?

This trial has 5 study locations across California, Colorado, Connecticut, Illinois, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure With Reduced Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.